<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922386</url>
  </required_header>
  <id_info>
    <org_study_id>LBFX05 - PERSEPOLIS</org_study_id>
    <nct_id>NCT03922386</nct_id>
  </id_info>
  <brief_title>Safety and Electrical Performances of XFINE Leads</brief_title>
  <acronym>PERSEPOLIS</acronym>
  <official_title>ProspEctive Record of Safety and Electrical Performances Of XFINE Leads: an International Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroPort CRM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroPort CRM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to confirm the safety and the electrical performances of the
      XFINE passive pacing leads, for both right ventricular (RV) straight models and right atrial
      (RA) J-shape models, up to 12 months follow-up post implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be followed until 12 months follow-up post implant.

      At each follow-up visits (3, 6 and 12 months), electrical performances will be measured and
      safety will be monitored during the whole study duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Post market, multicenter, international, prospective, open label, two arms and longitudinal non comparative non randomized study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from XFINE lead-related complications</measure>
    <time_frame>at 6 months post implant</time_frame>
    <description>This endpoint will confirm the freedom from XFINE Lead-Related Complications (LRC) up to the 6 months post implant follow-up. The anticipated complication-free rate is 0.95, and will be compared against an a priori performance goal of 0.85.
An XFINE Lead-Related Complication (LRC) is defined as any XFINE (RA and/or RV) lead-related Serious Adverse Device Effect (SADE) that resulted in subject death or required an additional invasive intervention (excluding re-programming) and occurred within 6 months post implant. This endpoint will be assessed independently for each lead model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrical performances confirmation</measure>
    <time_frame>at 6 months post implant</time_frame>
    <description>This endpoint will characterize the XFINE lead performances in ensuring adequate Pacing Capture Thresholds (PCT) through 6 months post implant follow-up. The values assessed in this analysis are the PCT measured at 0.50 ms (or less) pulse width at 6 months follow-up visit. The PCT measured at 6 months will be compared against an a priori performance goal of 1.0V/0.5 ms, assuming an expected pacing threshold at 6 months of 0.8V/0.5 ms with a standard deviation of 0.5V. This endpoint will be assessed independently for each lead model.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>JX model</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with an RA XFINE lead (JX model)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TX model</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with an RV XFINE lead (TX model)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XFINE leads</intervention_name>
    <description>Pacemaker subjects with at least one XFINE passive lead</description>
    <arm_group_label>JX model</arm_group_label>
    <arm_group_label>TX model</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any subject newly implanted according to the most recent guidelines from the European
             Society of Cardiology (ESC) for less than10 days with:

               -  a Single Chamber (SR) or a Dual Chamber (DR) pacemaker from Microport CRM S.r.l.

               -  any right atrial and/or right ventricular XFINE lead

          2. Have reviewed, signed and dated the informed consent

        Exclusion Criteria:

          1. Included in another clinical study that could confound the results of this study such
             as studies involving intra-cardiac device

          2. Contraindication to a maximum single dose of 310 µg Dexamethasone Sodium Phosphate
             (DSP)

          3. Tricuspid valvular disease or tricuspid replacement heart valve (mechanical or tissue)
             only for subject with DR pacemaker

          4. Active myocarditis, pocket and/or lead infection

          5. Age less than 18 years old or under guardianship or kept in detention

          6. Life expectancy less than 1 year

          7. Known pregnancy, women breastfeeding or in childbearing age without an adequate
             contraceptive method

          8. Be unavailable for the scheduled follow-up associated with this clinical study or
             refusal to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Bardají, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Joan XXIII, Tarragona, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Guihard, Clinical Project Manager</last_name>
    <phone>+33 1 46 01 33 20</phone>
    <email>antoine.guihard@crm.microport.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerhard Askamp, Clinical Program Manager</last_name>
    <phone>+31 6 8367 2934</phone>
    <email>gerhard.askamp@crm.microport.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica San Carlo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ezio Aimè, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Bardari, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Bardajì, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Pearse, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

